FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996293133> ?p ?o ?g. }

• W2996293133 endingPage "S604" @default.
• W2996293133 startingPage "S604" @default.
• W2996293133 abstract "The risk sharing agreement (RSA) was applied to anticancer and rare disease drugs as a policy to improve patient accessibility in Korea. The purpose of this study is to analyze the achievement of the implementation and the status of system operation since the implementation of RSA. 422 drugs evaluated from 2009 to 2018 by the Pharmaceutical Benefits Committee were analyzed. We divided the period into before and after the introduction of RSA (2009 ∼ 2013 vs. 2014 ∼ 2018) and compared the reimbursement recommendation rate and the time required for evaluation at HIRA focused on anticancer and rare drugs. In addition, the ratio, type, and characteristics (improvement of clinical usefulness, renewal of contract, etc.) of RSA applied drugs were analyzed among the listed drugs within five years. Anticancer and rare disease drugs have increased their recommendation rate(51.7%→74.2%, 73.2%→83%, respectively) and review period was shortened after the introduction of the system. 17 drugs have been listed through RSA for 5 years, which accounted for 20% (17/87) of the listed anticancer and rare disease drugs (N=87). Most of the RSA applied drugs were reviewed as economic evaluation (N=15) because of the improvement in their clinical usefulness, accounting for 51.7% (15/29) of the total economic evaluation drugs over the same period. As for the RSA types, there were refund (N=12), utilization cap (N=4) and coverage with evidence development (N=1). After the listing, some changes occurred like the termination of contracts for the development of evidence (N=1) or listing of alternative drugs (N=3). After the implementation of RSA, patients have better accessibility to medicines with the improvement in reimbursement recommendation rate and shortened review period. It especially seems to have had a positive impact on improving the accessibility of drugs with improved effects." @default.
• W2996293133 created "2019-12-26" @default.
• W2996293133 creator A5016872184 @default.
• W2996293133 creator A5019114194 @default.
• W2996293133 creator A5059563152 @default.
• W2996293133 creator A5079921448 @default.
• W2996293133 date "2019-11-01" @default.
• W2996293133 modified "2023-09-30" @default.
• W2996293133 title "PDG45 5 YEAR STATUS OF RISK SHARING AGREEMENT IN KOREA SINCE THE IMPLEMENTATION" @default.
• W2996293133 doi "https://doi.org/10.1016/j.jval.2019.09.1059" @default.
• W2996293133 hasPublicationYear "2019" @default.
• W2996293133 type Work @default.
• W2996293133 sameAs 2996293133 @default.
• W2996293133 citedByCount "0" @default.
• W2996293133 crossrefType "journal-article" @default.
• W2996293133 hasAuthorship W2996293133A5016872184 @default.
• W2996293133 hasAuthorship W2996293133A5019114194 @default.
• W2996293133 hasAuthorship W2996293133A5059563152 @default.
• W2996293133 hasAuthorship W2996293133A5079921448 @default.
• W2996293133 hasBestOaLocation W29962931331 @default.
• W2996293133 hasConcept C10138342 @default.
• W2996293133 hasConcept C126322002 @default.
• W2996293133 hasConcept C144133560 @default.
• W2996293133 hasConcept C160735492 @default.
• W2996293133 hasConcept C17744445 @default.
• W2996293133 hasConcept C199539241 @default.
• W2996293133 hasConcept C2779703844 @default.
• W2996293133 hasConcept C2779820595 @default.
• W2996293133 hasConcept C512399662 @default.
• W2996293133 hasConcept C71924100 @default.
• W2996293133 hasConceptScore W2996293133C10138342 @default.
• W2996293133 hasConceptScore W2996293133C126322002 @default.
• W2996293133 hasConceptScore W2996293133C144133560 @default.
• W2996293133 hasConceptScore W2996293133C160735492 @default.
• W2996293133 hasConceptScore W2996293133C17744445 @default.
• W2996293133 hasConceptScore W2996293133C199539241 @default.
• W2996293133 hasConceptScore W2996293133C2779703844 @default.
• W2996293133 hasConceptScore W2996293133C2779820595 @default.
• W2996293133 hasConceptScore W2996293133C512399662 @default.
• W2996293133 hasConceptScore W2996293133C71924100 @default.
• W2996293133 hasLocation W29962931331 @default.
• W2996293133 hasOpenAccess W2996293133 @default.
• W2996293133 hasPrimaryLocation W29962931331 @default.
• W2996293133 hasRelatedWork W1972636470 @default.
• W2996293133 hasRelatedWork W1999940705 @default.
• W2996293133 hasRelatedWork W2112872841 @default.
• W2996293133 hasRelatedWork W2766912110 @default.
• W2996293133 hasRelatedWork W2931204110 @default.
• W2996293133 hasRelatedWork W3080930447 @default.
• W2996293133 hasRelatedWork W3107173107 @default.
• W2996293133 hasRelatedWork W3123706592 @default.
• W2996293133 hasRelatedWork W3211482644 @default.
• W2996293133 hasRelatedWork W4283528738 @default.
• W2996293133 hasVolume "22" @default.
• W2996293133 isParatext "false" @default.
• W2996293133 isRetracted "false" @default.
• W2996293133 magId "2996293133" @default.
• W2996293133 workType "article" @default.